Side effects of immunotherapy a constant challenge for oncologistsScotté, Florian; Ratta, Raffaele; Beuzeboc, PhilippeCurrent Opinion in Oncology: July 2019 - Volume 31 - Issue 4 - p 280–285 doi: 10.1097/CCO.0000000000000541 SUPPORTIVE CARE: Edited by Jean A. Klastersky Buy Abstract Author InformationAuthors Article MetricsMetrics Purpose of review Immunotherapeutic strategies have become the new paradigm of cancer care, through their new targeting and safety profile approach, and, de facto, their new monitoring and safety management challenges. Recent findings Generalities and specificities of the toxicity management related to immune checkpoint inhibitors (ICIs) are highlighted. Predictive factors of safety are issue of research and the challenge of prevention as well as monitoring are huge to alleviate toxicities and enhance safety and efficacy. Particular situations like steroids association and cost-effectiveness approach are summarized. Summary Patients as well as general practitioners, including health-caregivers, should be informed before ICI initiation of the different alert symptoms which should precede immune-related adverse events. Oncology and Supportive Care Department, Hôpital Foch, Suresnes, France Correspondence to Florian Scotté, MD, PhD, Oncology and Supportive Care Department, Hôpital Foch, 40 Rue Worth, 92151 Suresnes, France. Tel: +33 146252868; e-mail: firstname.lastname@example.org Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.